Connection

Michael Hallek to Time Factors

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Time Factors.
Michael Hallek
Connection Strength
0.087
Time Factors
  1. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 09; 19(9):1215-1228.
    View in: PubMed
    Score: 0.035
  2. Role and timing of new drugs in CLL. Hematol Oncol. 2017 Jun; 35 Suppl 1:30-32.
    View in: PubMed
    Score: 0.032
  3. Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia. Bone Marrow Transplant. 2021 03; 56(3):716-719.
    View in: PubMed
    Score: 0.010
  4. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.